JP2017522862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522862A5 JP2017522862A5 JP2016571017A JP2016571017A JP2017522862A5 JP 2017522862 A5 JP2017522862 A5 JP 2017522862A5 JP 2016571017 A JP2016571017 A JP 2016571017A JP 2016571017 A JP2016571017 A JP 2016571017A JP 2017522862 A5 JP2017522862 A5 JP 2017522862A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- isolated
- car
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 15
- 210000004027 cells Anatomy 0.000 claims 13
- 230000003211 malignant Effects 0.000 claims 6
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 4
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 3
- 102100005826 CD19 Human genes 0.000 claims 3
- 101700087100 CD19 Proteins 0.000 claims 3
- 102100019461 CD28 Human genes 0.000 claims 3
- 101700033362 CD28 Proteins 0.000 claims 3
- 102100008191 CD8A Human genes 0.000 claims 3
- 101700054655 CD8A Proteins 0.000 claims 3
- 210000004693 NK cell Anatomy 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 102100019459 CD27 Human genes 0.000 claims 2
- 101700056583 CD27 Proteins 0.000 claims 2
- 230000003834 intracellular Effects 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Description
関連出願の相互参照
本特許出願は2014年6月2日出願の米国仮特許出願第62/006,313号（参照により組み込まれる）の利益を主張する。
連邦政府の助成による研究又は開発に関する陳述
本発明は、連邦政府の支援を受け、プロジェクト番号Z01 BC001415の下、米国国立衛生研究所、米国国立がん研究所によりなされた。本発明において、連邦政府は一定の権利を有する。
本特許出願は2014年6月2日出願の米国仮特許出願第62/006,313号（参照により組み込まれる）の利益を主張する。
連邦政府の助成による研究又は開発に関する陳述
本発明は、連邦政府の支援を受け、プロジェクト番号Z01 BC001415の下、米国国立衛生研究所、米国国立がん研究所によりなされた。本発明において、連邦政府は一定の権利を有する。
Claims (12)
- CD19に対する単離又は精製されたキメラ抗原受容体（CAR）であって、配列番号1、配列番号2、配列番号3、配列番号4、配列番号5、配列番号6、配列番号7、配列番号8、配列番号9、配列番号10、配列番号11、配列番号12又は配列番号13のアミノ酸配列を含む、CAR。
- 配列番号4又は配列番号9に存在する以下の要素：（i）細胞外スペーサー、（ii）ヒトCD8α分子に由来する膜貫通ドメイン、並びに（iii）（a）ヒトCD28分子及び／又はヒトCD27分子、及び（b）ヒトCD3ζ分子に由来する細胞内T細胞シグナリングドメイン、を含む単離又は精製されたキメラ抗原受容体（CAR）。
- 配列番号10又は配列番号11に存在する以下の要素：（i）細胞外スペーサー、（ii）ヒトCD8α分子に由来する膜貫通ドメイン、並びに（iii）ヒトCD28分子及び／又はヒトCD27分子、及び（b）FcεRIガンマ鎖に由来する細胞内T細胞シグナリングドメイン、を含む単離又は精製されたキメラ抗原受容体（CAR）。
- 配列番号12又は配列番号13に存在する以下の要素：（i）細胞外スペーサー、（ii）ヒトCD8α分子に由来する膜貫通ドメイン、並びに（iii）ヒトCD28分子及びFcεRIガンマ鎖に由来する細胞内T細胞シグナリングドメイン、を含む単離又は精製されたキメラ抗原受容体（CAR）。
- 請求項1〜４のいずれか一項に記載のCARをコードする、単離又は精製された核酸。
- 請求項5に記載の単離又は精製された核酸を含む、ベクター。
- 請求項6に記載のベクターを含む、単離されたT細胞又はNK細胞。
- がんを治療又は予防するための医薬組成物であって、前記医薬組成物が、活性成分として、請求項1〜4のいずれか一項に記載のCAR、請求項5に記載の単離又は精製された核酸、請求項6に記載のベクター、又は単離又は精製されたT細胞又はNK細胞を含む、医薬組成物。
- インビトロにおいて、悪性B細胞を破壊する方法であって、前記方法が、請求項7に記載の単離されたT細胞又はNK細胞の1つ以上を、CD19を発現する悪性B細胞集団と接触させることを含み、それにより、CARが悪性B細胞上でCD19と結合し、悪性B細胞が破壊される、方法。
- 悪性B細胞がリンパ腫細胞である、請求項9に記載の方法。
- 悪性B細胞が白血病細胞である、請求項9に記載の方法。
- キメラ抗原受容体（CAR）を発現する細胞の作製方法であって、前記方法が、請求項1〜4のいずれか一項に記載のCARをコードするベクターをT細胞又はNK細胞に導入することを含む、方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462006313P | 2014-06-02 | 2014-06-02 | |
| US62/006,313 | 2014-06-02 | ||
| PCT/US2015/033473 WO2015187528A1 (en) | 2014-06-02 | 2015-06-01 | Chimeric antigen receptors targeting cd-19 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191748A Division JP7004470B2 (ja) | 2014-06-02 | 2020-11-18 | Ｃｄ－１９を標的とするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522862A JP2017522862A (ja) | 2017-08-17 |
| JP2017522862A5 true JP2017522862A5 (ja) | 2018-07-19 |
| JP6797693B2 JP6797693B2 (ja) | 2020-12-09 |
Family
ID=53398220
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571017A Active JP6797693B2 (ja) | 2014-06-02 | 2015-06-01 | Ｃｄ−１９を標的とするキメラ抗原受容体 |
| JP2020191748A Active JP7004470B2 (ja) | 2014-06-02 | 2020-11-18 | Ｃｄ－１９を標的とするキメラ抗原受容体 |
| JP2021215427A Pending JP2022061988A (ja) | 2014-06-02 | 2021-12-29 | Ｃｄ－１９を標的とするキメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191748A Active JP7004470B2 (ja) | 2014-06-02 | 2020-11-18 | Ｃｄ－１９を標的とするキメラ抗原受容体 |
| JP2021215427A Pending JP2022061988A (ja) | 2014-06-02 | 2021-12-29 | Ｃｄ－１９を標的とするキメラ抗原受容体 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10287350B2 (ja) |
| EP (2) | EP3798233A1 (ja) |
| JP (3) | JP6797693B2 (ja) |
| KR (1) | KR20170013941A (ja) |
| CN (1) | CN106536564B (ja) |
| AU (2) | AU2015270912B9 (ja) |
| CA (1) | CA2951045A1 (ja) |
| ES (1) | ES2836743T3 (ja) |
| IL (3) | IL249305B (ja) |
| MX (2) | MX2016015834A (ja) |
| SG (1) | SG11201609960QA (ja) |
| WO (1) | WO2015187528A1 (ja) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170013941A (ko) * | 2014-06-02 | 2017-02-07 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Cd-19를 표적화하는 키메라 항원 수용체 |
| WO2016149578A1 (en) | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-cd22-anti-cd19 chimeric antigen receptors |
| CA2994829A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| CN105906720A (zh) * | 2016-05-16 | 2016-08-31 | 武汉汉密顿生物科技股份有限公司 | 靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用 |
| CN105949324B (zh) * | 2016-06-30 | 2019-08-27 | 上海恒润达生生物科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
| CN105949325B (zh) * | 2016-07-08 | 2019-07-16 | 重庆精准生物技术有限公司 | 包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用 |
| JP7160482B2 (ja) * | 2016-09-02 | 2022-10-25 | レンティジェン・テクノロジー・インコーポレイテッド | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
| CN107936120B (zh) * | 2016-10-13 | 2021-03-09 | 上海赛比曼生物科技有限公司 | Cd19靶向性的嵌合抗原受体及其制法和应用 |
| CN110462040A (zh) | 2017-01-10 | 2019-11-15 | 英特拉克森公司 | 通过新基因开关表达系统调节多肽的表达 |
| US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| CA3062506A1 (en) | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| IL270990B2 (en) | 2017-06-07 | 2024-02-01 | Precigen Inc | Expression of new cell markers |
| EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
| US20200215112A1 (en) * | 2017-08-09 | 2020-07-09 | Ctg Pharma Ltd. | Chimeric antigen receptor for her2/neu and t-cells expressing same |
| US20200316122A1 (en) | 2017-10-11 | 2020-10-08 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of producing t cell populations using p38 mapk inhibitors |
| WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| KR102165934B1 (ko) * | 2017-12-22 | 2020-10-15 | 앱클론(주) | 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도 |
| US20210052647A1 (en) | 2018-02-09 | 2021-02-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Tethered interleukin-15 and interleukin-21 |
| WO2019154313A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| KR20210008502A (ko) * | 2018-05-11 | 2021-01-22 | 크리스퍼 테라퓨틱스 아게 | 암을 치료하기 위한 방법 및 조성물 |
| WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| CN108841792A (zh) * | 2018-06-14 | 2018-11-20 | 浙江大学 | 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用 |
| CN108864307A (zh) * | 2018-07-23 | 2018-11-23 | 北京多赢时代科技有限公司 | 信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用 |
| CN110819678A (zh) * | 2018-08-07 | 2020-02-21 | 上海恒润达生生物科技有限公司 | 一种评估cart细胞有效性的方法 |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
| WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| WO2020114358A1 (zh) * | 2018-12-03 | 2020-06-11 | 广东东阳光药业有限公司 | Cd19抗体及其应用 |
| CA3122762A1 (en) | 2018-12-12 | 2020-06-18 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| CN109734813B (zh) | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| RU2742000C2 (ru) * | 2019-03-13 | 2021-02-01 | Общество С Ограниченной Ответственностью "Анабион" | Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| CA3138633A1 (en) * | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| JP2022531911A (ja) | 2019-05-07 | 2022-07-12 | グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド | Ｂｃｍａを標的とする操作された免疫細胞及びその使用 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2020261219A1 (en) * | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
| AU2020307673A1 (en) * | 2019-06-27 | 2022-01-20 | Eutilex Co., Ltd. | Chimeric antigen receptor with 4-1BB costimulatory domain |
| CN110305849B (zh) * | 2019-08-01 | 2021-03-30 | 广东万海细胞生物科技有限公司 | 稳定表达car的t细胞及其制备方法与应用 |
| US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| CA3158122A1 (en) * | 2019-11-13 | 2021-05-20 | Hui Yu | Manufacturing process for making t cells expressing chimeric antigen receptors |
| JP2023517011A (ja) | 2020-03-05 | 2023-04-21 | ネオティーエックス セラピューティクス リミテッド | 免疫細胞を用いて癌を治療するための方法および組成物 |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CA3191211A1 (en) | 2020-09-08 | 2022-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell phenotypes associated with response to adoptive cell therapy |
| US20240018210A1 (en) | 2020-11-13 | 2024-01-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| JP2024502094A (ja) | 2020-12-30 | 2024-01-17 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| WO2022180586A1 (en) * | 2021-02-25 | 2022-09-01 | Senthil Natesan | Car t-cell product and method of preparation thereof |
| EP4298250A1 (en) | 2021-02-26 | 2024-01-03 | Fundació Institut de Recerca Contra la Leucèmia Josep Carreras | Markers of prediction of response to car t cell therapy |
| WO2023017544A1 (en) * | 2021-08-12 | 2023-02-16 | Cellogen Therapeutics Pvt. Ltd. | Chimeric antigen receptors (car) for b cell malignancies |
| CA3222263A1 (en) | 2021-08-13 | 2023-02-16 | Adrian GOTTSCHLICH | Anti-csf1r car expressing lymphocytes for targeted tumor therapy |
| WO2023130040A2 (en) | 2021-12-31 | 2023-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell therapy with vaccination as a combination immunotherapy against cancer |
| US20230210900A1 (en) * | 2022-01-04 | 2023-07-06 | Kyverna Therapeutics, Inc. | Methods for treating autoimmune diseases |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| IN165717B (ja) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| CN101636502B (zh) * | 2006-12-13 | 2014-06-04 | 梅达雷克斯有限责任公司 | 结合cd19的人类抗体及其用途 |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| CA2678451A1 (en) | 2007-02-20 | 2008-08-28 | Robert A. Horlick | Somatic hypermutation systems |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| WO2011041093A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| BR122021026173B1 (pt) | 2010-12-09 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | Composição farmacêutica |
| CN103596981B (zh) * | 2011-04-08 | 2017-06-16 | 美国卫生和人力服务部 | 抗‑表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途 |
| WO2013123061A1 (en) * | 2012-02-13 | 2013-08-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013154760A1 (en) * | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| KR20170013941A (ko) * | 2014-06-02 | 2017-02-07 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Cd-19를 표적화하는 키메라 항원 수용체 |
-
2015
- 2015-06-01 KR KR1020167036828A patent/KR20170013941A/ko active IP Right Grant
- 2015-06-01 CN CN201580033802.5A patent/CN106536564B/zh active Active
- 2015-06-01 EP EP20197459.9A patent/EP3798233A1/en active Pending
- 2015-06-01 AU AU2015270912A patent/AU2015270912B9/en active Active
- 2015-06-01 SG SG11201609960QA patent/SG11201609960QA/en unknown
- 2015-06-01 EP EP15729304.4A patent/EP3149044B1/en active Active
- 2015-06-01 JP JP2016571017A patent/JP6797693B2/ja active Active
- 2015-06-01 CA CA2951045A patent/CA2951045A1/en active Pending
- 2015-06-01 US US15/315,533 patent/US10287350B2/en active Active
- 2015-06-01 MX MX2016015834A patent/MX2016015834A/es unknown
- 2015-06-01 WO PCT/US2015/033473 patent/WO2015187528A1/en active Application Filing
- 2015-06-01 ES ES15729304T patent/ES2836743T3/es active Active
-
2016
- 2016-11-30 IL IL249305A patent/IL249305B/en active IP Right Grant
- 2016-12-01 MX MX2021006239A patent/MX2021006239A/es unknown
-
2019
- 2019-03-21 US US16/360,281 patent/US11236161B2/en active Active
-
2020
- 2020-11-11 AU AU2020267211A patent/AU2020267211A1/en active Pending
- 2020-11-18 JP JP2020191748A patent/JP7004470B2/ja active Active
-
2021
- 2021-05-25 IL IL283423A patent/IL283423B/en unknown
- 2021-12-21 US US17/557,845 patent/US20220153838A1/en active Pending
- 2021-12-29 JP JP2021215427A patent/JP2022061988A/ja active Pending
-
2022
- 2022-03-13 IL IL291292A patent/IL291292A/en unknown
- 2022-03-16 US US17/696,249 patent/US20220204619A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522862A5 (ja) | ||
| IL292650B1 (en) | IL13RA2-targeted chimeric antigen receptor T cells | |
| Benmebarek et al. | Killing mechanisms of chimeric antigen receptor (CAR) T cells | |
| JP2018520679A5 (ja) | ||
| BR112020007576A2 (pt) | composições e métodos para degradação de proteína seletiva | |
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| WO2018187613A3 (en) | Anti-icos agonist antibodies and uses thereof | |
| JP2017537627A5 (ja) | ||
| MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
| MX2022011309A (es) | Receptores de celulas t. | |
| BR112018008442A2 (pt) | receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados | |
| JP2019528769A5 (ja) | ||
| RU2014144143A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток | |
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| MY193112A (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| AU2017248120A1 (en) | T cell receptors | |
| RU2017105515A (ru) | Сигнальная система | |
| JP2018514204A5 (ja) | ||
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| WO2018183888A3 (en) | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling | |
| JP2017529851A5 (ja) | ||
| EA201790953A1 (ru) | Изменение экспрессии гена в cart-клетках и их применения | |
| JP2017513478A5 (ja) | ||
| JP2016514457A5 (ja) |